Amanjot Kaur
Amanjot Kaur has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Arindam Ray
Gates Foundation, New Delhi 110067, India
12 shared publications - Rhythm Hora
John Snow India, New Delhi, India
10 shared publications - Amrita Kumari
Bill & Melinda Gates Foundation, India
8 shared publications - Rashmi Mehra
John Snow India Private Limited, New Delhi, India
8 shared publications - Seema Singh Koshal
John Snow India Private Limited, New Delhi, India
8 shared publications - Syed F. Quadri
John Snow India, New Delhi, India
8 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Qeios Ltd
Review of: "The Global Polio Eradication Initiative has done well to introduce 3 doses of the Inactivated Poliovirus Vaccine in Afghanistan"
The manuscript is very vaguely written throughout, with emphasis only on the assumption that IPV would be the best way forward for polio elimination, especially targeting type 1 polio. There should be references or evidence to support this statement...
- 30 March 2026
- Published by Qeios Ltd
Open AccessReview of: "The Global Polio Eradication Initiative has done well to introduce 3 doses of the Inactivated Poliovirus Vaccine in Afghanistan"
The manuscript is very vaguely written throughout, with emphasis only on the assumption that IPV would be the best way forward for polio elimination, especially targeting type 1 polio. There should be references or evidence to support this statement...
- Open Access
- 24 October 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e86326
Stakeholder Experiences with the PCV Chatbot as a Complementary Capacity-Building Tool for Frontline Health Workers in India: a Qualitative Study (Preprint)
Pneumonia remains the leading cause of mortality in individuals aged 5 years or younger globally, with India bearing a disproportionately high burden. The introduction of the pneumococcal conjugate vaccine (PCV) in India necessitated innovative approaches to support frontline health workers (FLHWs), particularly in remote settings. To address this, a customizable WhatsApp-based PCV chatbot was developed as a complementary tool to traditional training and reference materials. This study aimed to document the opportunities, challenges, and mitigation measures encountered during the development and rollout of the PCV chatbot, and to explore its use and user experience as a capacity-building and support tool for FLHWs during new vaccine introduction. A qualitative study was conducted across 4 Indian states-Arunachal Pradesh, Delhi, Karnataka, and West Bengal-using purposive sampling at the district and block levels. Data collection involved key informant interviews with immunization officials and chatbot developers, and focus group discussions with auxiliary nurse midwives. A Likert scale-based tool captured quantitative feedback on user satisfaction. Stakeholders appreciated the chatbot's accessibility, familiarity (through WhatsApp), and multilingual functionality. Most auxiliary nurse midwives found it easy to use and rated responses highly for completeness and usefulness. The chatbot enabled immediate access to information, saving time and bridging gaps, especially when traditional training was delayed or unavailable in hard-to-reach areas. Challenges included occasional technical issues, limited content related to dropout and left-out scenarios, and difficulties in typing regional languages. Recommendations included implementing predictive text, expanding scenario coverage, and strengthening user-centered design and field testing. The PCV chatbot demonstrated acceptability and perceived value as an on-demand knowledge tool among FLHWs. Continuous user-driven refinement, expanded content, and enhanced usability are essential for its scalability and sustained use in vaccine introduction and capacity-building efforts.
- 24 October 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e86326
Open AccessStakeholder Experiences with the PCV Chatbot as a Complementary Capacity-Building Tool for Frontline Health Workers in India: a Qualitative Study (Preprint)
Pneumonia remains the leading cause of mortality in individuals aged 5 years or younger globally, with India bearing a disproportionately high burden. The introduction of the pneumococcal conjugate vaccine (PCV) in India necessitated innovative approaches to support frontline health workers (FLHWs), particularly in remote settings. To address this, a customizable WhatsApp-based PCV chatbot was developed as a complementary tool to traditional training and reference materials. This study aimed to document the opportunities, challenges, and mitigation measures encountered during the development and rollout of the PCV chatbot, and to explore its use and user experience as a capacity-building and support tool for FLHWs during new vaccine introduction. A qualitative study was conducted across 4 Indian states-Arunachal Pradesh, Delhi, Karnataka, and West Bengal-using purposive sampling at the district and block levels. Data collection involved key informant interviews with immunization officials and chatbot developers, and focus group discussions with auxiliary nurse midwives. A Likert scale-based tool captured quantitative feedback on user satisfaction. Stakeholders appreciated the chatbot's accessibility, familiarity (through WhatsApp), and multilingual functionality. Most auxiliary nurse midwives found it easy to use and rated responses highly for completeness and usefulness. The chatbot enabled immediate access to information, saving time and bridging gaps, especially when traditional training was delayed or unavailable in hard-to-reach areas. Challenges included occasional technical issues, limited content related to dropout and left-out scenarios, and difficulties in typing regional languages. Recommendations included implementing predictive text, expanding scenario coverage, and strengthening user-centered design and field testing. The PCV chatbot demonstrated acceptability and perceived value as an on-demand knowledge tool among FLHWs. Continuous user-driven refinement, expanded content, and enhanced usability are essential for its scalability and sustained use in vaccine introduction and capacity-building efforts.
- Open Access
- 24 October 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Stakeholder Experiences with the PCV Chatbot as a Complementary Capacity-Building Tool for Frontline Health Workers in India (Preprint)
BACKGROUND Pneumonia remains the leading cause of under-five mortality globally, with India bearing a disproportionately high burden. The introduction of the Pneumococcal Conjugate Vaccine (PCV) in India necessitated innovative approaches to support frontline health workers (FLHWs), particularly in remote settings. To address this, a customizable WhatsApp-based PCV chatbot was developed as a complementary tool to traditional training and reference materials. OBJECTIVE To document the opportunities, challenges, and mitigation measures encountered during the development and roll-out of the PCV chatbot, and to assess its utility and user experience as a capacity-building and support tool for FLHWs during new vaccine introduction. METHODS A qualitative study was conducted across four Indian states—Arunachal Pradesh, Delhi, Karnataka, and West Bengal—using purposive sampling at the district and block levels. Data collection involved key informant interviews (KIIs) with immunization officials and chatbot developers, and focus group discussions (FGDs) with Auxiliary Nurse Midwives (ANMs). A Likert scale-based tool captured quantitative feedback on user satisfaction. RESULTS Stakeholders appreciated the chatbot’s accessibility, familiarity (through WhatsApp), and multilingual functionality. Most ANMs found it easy to use and rated responses highly for completeness and usefulness. The chatbot enabled immediate access to information, saving time and bridging gaps, especially when traditional training was delayed or unavailable in hard-to-reach areas. Challenges included occasional technical issues, limited content related to dropout and left-out scenarios, and difficulties in typing regional languages. Recommendations included implementing predictive text, expanding scenario coverage, and strengthening user-centered design and field testing. CONCLUSIONS The PCV chatbot demonstrated acceptability and perceived value as an on-demand knowledge tool among FLHWs. Continuous user-driven refinement, expanded content, and enhanced usability are essential for its scalability and sustained utility in vaccine introduction and capacity-building efforts. CLINICALTRIAL IRB Certificate Number: Convergent IRB/2024-25/015
- 24 October 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessStakeholder Experiences with the PCV Chatbot as a Complementary Capacity-Building Tool for Frontline Health Workers in India (Preprint)
BACKGROUND Pneumonia remains the leading cause of under-five mortality globally, with India bearing a disproportionately high burden. The introduction of the Pneumococcal Conjugate Vaccine (PCV) in India necessitated innovative approaches to support frontline health workers (FLHWs), particularly in remote settings. To address this, a customizable WhatsApp-based PCV chatbot was developed as a complementary tool to traditional training and reference materials. OBJECTIVE To document the opportunities, challenges, and mitigation measures encountered during the development and roll-out of the PCV chatbot, and to assess its utility and user experience as a capacity-building and support tool for FLHWs during new vaccine introduction. METHODS A qualitative study was conducted across four Indian states—Arunachal Pradesh, Delhi, Karnataka, and West Bengal—using purposive sampling at the district and block levels. Data collection involved key informant interviews (KIIs) with immunization officials and chatbot developers, and focus group discussions (FGDs) with Auxiliary Nurse Midwives (ANMs). A Likert scale-based tool captured quantitative feedback on user satisfaction. RESULTS Stakeholders appreciated the chatbot’s accessibility, familiarity (through WhatsApp), and multilingual functionality. Most ANMs found it easy to use and rated responses highly for completeness and usefulness. The chatbot enabled immediate access to information, saving time and bridging gaps, especially when traditional training was delayed or unavailable in hard-to-reach areas. Challenges included occasional technical issues, limited content related to dropout and left-out scenarios, and difficulties in typing regional languages. Recommendations included implementing predictive text, expanding scenario coverage, and strengthening user-centered design and field testing. CONCLUSIONS The PCV chatbot demonstrated acceptability and perceived value as an on-demand knowledge tool among FLHWs. Continuous user-driven refinement, expanded content, and enhanced usability are essential for its scalability and sustained utility in vaccine introduction and capacity-building efforts. CLINICALTRIAL IRB Certificate Number: Convergent IRB/2024-25/015
- Open Access
- 5 August 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e70322
Digital Media Coverage of Respiratory Syncytial Virus-Related News in India: Mixed Methods Content Analysis of Disease Burden and Intervention
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children younger than 5 years of age. Given the high morbidity and mortality associated with RSV in India, the introduction of a vaccine against RSV will potentially reduce the disease’s burden. However, vaccine acceptance is influenced by public perception, which is shaped by information disseminated through media sources. This study aims to explore the landscape of RSV–related news coverage in India’s digital media. Objective: This study aims to conduct a comprehensive content analysis to explore the landscape of RSV–related news coverage in India’s digital media. Methods: Media content analysis was retrospectively conducted by a digital search for all related news pieces in the trustworthy brands of 4 trusted newspapers (Hindustan Times, The Hindu, The Indian Express, and The Times of India) and 3 news channel websites (India Today, NDTV news, and News 18), between November 1, 2022, and October 31, 2023. A total of 58 news pieces were retrieved using selected keywords, with inclusion criteria encompassing English-language news pieces with RSV–specific content. Two reviewers compiled, coded, and analyzed the content. Quantitative data were analyzed descriptively, while qualitative content analysis assessed the emotional tone and sentiment of the pieces. Results: The findings revealed significant digital media coverage on RSV infection and the potential vaccines. The majority of news pieces (53/58, 91%) discussed RSV signs and symptoms, with 64% (37/58) addressing the disease severity and 36% (21/58) highlighting its seasonal surge. However, only 5% (3/58) focused on diagnostic aids. Additionally, 41% (24/58) of news pieces discussed RSV in the context of COVID-19. Regarding the vaccine, 29% (17/58) of news pieces mentioned it, with 26% (15/58) highlighting manufacturers such as Pfizer and GlaxoSmithKline (GSK). Positive sentiment was found in 35% (20/58) of news pieces, while 43% (25/58) exhibited negative sentiment, often related to the disease burden and severity. Emotional tone analysis revealed that 74% (43/58) of news pieces contained emotional elements, with 58% (25/43) expressing negative emotions (eg, concern and anxiety), particularly about hospitalizations and deaths. In contrast, a positive tone was emulated in the frequent mentions of the RSV vaccines as safe, effective, and approved. Conclusions: The analysis revealed significant coverage of RSV–related news in India’s digital media, with a focus on disease severity and hospitalizations. While positive sentiment was expressed in coverage of the RSV vaccine, negative sentiments dominated discussions on the disease burden. However, considering the limited number of news pieces, the study highlights the need for improved media coverage to raise awareness about the disease and its preventive strategies. Further research should explore the implications of the overlap between RSV and COVID-19 in media coverage and the limited focus on RSV diagnostics, with a focus on understanding how these factors impact public health outcomes.
- 5 August 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e70322
Open AccessDigital Media Coverage of Respiratory Syncytial Virus-Related News in India: Mixed Methods Content Analysis of Disease Burden and Intervention
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children younger than 5 years of age. Given the high morbidity and mortality associated with RSV in India, the introduction of a vaccine against RSV will potentially reduce the disease’s burden. However, vaccine acceptance is influenced by public perception, which is shaped by information disseminated through media sources. This study aims to explore the landscape of RSV–related news coverage in India’s digital media. Objective: This study aims to conduct a comprehensive content analysis to explore the landscape of RSV–related news coverage in India’s digital media. Methods: Media content analysis was retrospectively conducted by a digital search for all related news pieces in the trustworthy brands of 4 trusted newspapers (Hindustan Times, The Hindu, The Indian Express, and The Times of India) and 3 news channel websites (India Today, NDTV news, and News 18), between November 1, 2022, and October 31, 2023. A total of 58 news pieces were retrieved using selected keywords, with inclusion criteria encompassing English-language news pieces with RSV–specific content. Two reviewers compiled, coded, and analyzed the content. Quantitative data were analyzed descriptively, while qualitative content analysis assessed the emotional tone and sentiment of the pieces. Results: The findings revealed significant digital media coverage on RSV infection and the potential vaccines. The majority of news pieces (53/58, 91%) discussed RSV signs and symptoms, with 64% (37/58) addressing the disease severity and 36% (21/58) highlighting its seasonal surge. However, only 5% (3/58) focused on diagnostic aids. Additionally, 41% (24/58) of news pieces discussed RSV in the context of COVID-19. Regarding the vaccine, 29% (17/58) of news pieces mentioned it, with 26% (15/58) highlighting manufacturers such as Pfizer and GlaxoSmithKline (GSK). Positive sentiment was found in 35% (20/58) of news pieces, while 43% (25/58) exhibited negative sentiment, often related to the disease burden and severity. Emotional tone analysis revealed that 74% (43/58) of news pieces contained emotional elements, with 58% (25/43) expressing negative emotions (eg, concern and anxiety), particularly about hospitalizations and deaths. In contrast, a positive tone was emulated in the frequent mentions of the RSV vaccines as safe, effective, and approved. Conclusions: The analysis revealed significant coverage of RSV–related news in India’s digital media, with a focus on disease severity and hospitalizations. While positive sentiment was expressed in coverage of the RSV vaccine, negative sentiments dominated discussions on the disease burden. However, considering the limited number of news pieces, the study highlights the need for improved media coverage to raise awareness about the disease and its preventive strategies. Further research should explore the implications of the overlap between RSV and COVID-19 in media coverage and the limited focus on RSV diagnostics, with a focus on understanding how these factors impact public health outcomes.
- Open Access
- 27 May 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e69729
Google Trends for the Human Papillomavirus Vaccine in India From 2010 to 2024: Infodemiological Study
Background: Human papillomavirus (HPV) is a leading cause of cervical cancer. It has a substantial impact on global public health, with low- and middle-income countries, including India, facing the highest burden. In 2022, India reported 127,526 new cases and 79,906 deaths due to cervical cancer, projected to increase by 61% by 2040. Although the National Technical Advisory Group on Immunization recommended the HPV vaccine for cervical cancer prevention, it is yet to be a part of India’s universal immunization program. Objective: This study aims to examine online interest in the HPV vaccine in India from January 2010 to April 2024 using Google Trends. Methods: A cross-sectional analysis of Google Trends data was performed, using the relative search volume to track interest on a scale of 0‐100. Trends were analyzed annually using 1-way ANOVA and joinpoint regression to identify significant changes in search behavior related to public health events. Statistical significance was set at P<.05. Results: The average annual growth in HPV vaccine-related searches was 13.7% (95% CI 7.9%‐19.1%), with the highest relative search volume in 2024 (49.5) and the lowest in 2017 (3.38). Spikes in search interest aligned with key events like the 2018 National Technical Advisory Group on Immunization recommendation and the 2022 launch of the indigenous HPV vaccine. The results highlight online search data’s value in tracking public interest, which fluctuates in response to health policy changes or developments on social media. In India, targeted digital strategies will be vital for addressing vaccine hesitancy and increasing HPV vaccine uptake. Conclusions: Google Trends data can inform public health strategies by identifying periods of high interest, aiding in the promotion of HPV vaccination in India.
- 27 May 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e69729
Open AccessGoogle Trends for the Human Papillomavirus Vaccine in India From 2010 to 2024: Infodemiological Study
Background: Human papillomavirus (HPV) is a leading cause of cervical cancer. It has a substantial impact on global public health, with low- and middle-income countries, including India, facing the highest burden. In 2022, India reported 127,526 new cases and 79,906 deaths due to cervical cancer, projected to increase by 61% by 2040. Although the National Technical Advisory Group on Immunization recommended the HPV vaccine for cervical cancer prevention, it is yet to be a part of India’s universal immunization program. Objective: This study aims to examine online interest in the HPV vaccine in India from January 2010 to April 2024 using Google Trends. Methods: A cross-sectional analysis of Google Trends data was performed, using the relative search volume to track interest on a scale of 0‐100. Trends were analyzed annually using 1-way ANOVA and joinpoint regression to identify significant changes in search behavior related to public health events. Statistical significance was set at P<.05. Results: The average annual growth in HPV vaccine-related searches was 13.7% (95% CI 7.9%‐19.1%), with the highest relative search volume in 2024 (49.5) and the lowest in 2017 (3.38). Spikes in search interest aligned with key events like the 2018 National Technical Advisory Group on Immunization recommendation and the 2022 launch of the indigenous HPV vaccine. The results highlight online search data’s value in tracking public interest, which fluctuates in response to health policy changes or developments on social media. In India, targeted digital strategies will be vital for addressing vaccine hesitancy and increasing HPV vaccine uptake. Conclusions: Google Trends data can inform public health strategies by identifying periods of high interest, aiding in the promotion of HPV vaccination in India.
- Open Access
Chronicling the Journey of Pneumococcal Conjugate Vaccine Introduction in India
Background: Globally, pneumonia claims the lives of about 700,000 children under the age of 5 every year. Pneumococcal conjugate vaccine (PCV) was introduced in India phase-wise, beginning in high-burden states, and the rollout was completed nationwide by 2021—representing a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite the challenges posed by the COVID-19 pandemic, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, processes, and coordinated efforts of the various stakeholders involved that led to this successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to pneumonia burden and the efficacy and effectiveness of PCVs, along with documentation of PCV introduction and the scale-up was carried out. Results: The documentation of the PCV journey has been broken down into four sections: pre-introduction, PCV Phase-I introduction, pan-India rapid expansion, and the period post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased, reflecting successful immunization efforts. WUENIC, which is an annual WHO, and UNICEF estimates of national immunization coverage also show a positive trend in vaccination coverage (PCV booster coverage = 25% (2021), rising to 83% (2023), aligning with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). Conclusions: The phased rollout was an ambitious effort by the MoHFW, which was particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, along with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. Future studies on the role of PCVs in reducing antibiotic resistance and the economic benefits of PCV introduction could help policymakers sustain funding and prioritize vaccine procurement decisions.
Open AccessChronicling the Journey of Pneumococcal Conjugate Vaccine Introduction in India
Background: Globally, pneumonia claims the lives of about 700,000 children under the age of 5 every year. Pneumococcal conjugate vaccine (PCV) was introduced in India phase-wise, beginning in high-burden states, and the rollout was completed nationwide by 2021—representing a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite the challenges posed by the COVID-19 pandemic, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, processes, and coordinated efforts of the various stakeholders involved that led to this successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to pneumonia burden and the efficacy and effectiveness of PCVs, along with documentation of PCV introduction and the scale-up was carried out. Results: The documentation of the PCV journey has been broken down into four sections: pre-introduction, PCV Phase-I introduction, pan-India rapid expansion, and the period post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased, reflecting successful immunization efforts. WUENIC, which is an annual WHO, and UNICEF estimates of national immunization coverage also show a positive trend in vaccination coverage (PCV booster coverage = 25% (2021), rising to 83% (2023), aligning with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). Conclusions: The phased rollout was an ambitious effort by the MoHFW, which was particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, along with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. Future studies on the role of PCVs in reducing antibiotic resistance and the economic benefits of PCV introduction could help policymakers sustain funding and prioritize vaccine procurement decisions.
- Open Access
Stakeholders Perspectives on the Introduction of an Additional Injectable Vaccine Under the Universal Immunization Programme in India
Introduction: In 2023, India’s National Technical Advisory Group on Immunization (NTAGI) recommended the inclusion of typhoid conjugate vaccine (TCV) in the Universal Immunization Programme (UIP). However, introducing TCV, an additional injectable vaccine (AIV), will potentially increase the number of injections administered in a single visit to a maximum of five (if given at the 9 to 12 months touchpoint) or four (if given in the second year of life). In this context, the present study aimed to explore the perspectives of program managers, service providers, and caregivers regarding introduction of an AIV in a single visit under the UIP. Methods: A mixed-method study was undertaken wherein quantitative data was collected by telephonic surveys, and qualitative data by key informant interviews (KIIs) and focus group discussions (FGDs). Purposive sampling encompassed eight states, eight districts, eight planning units, and 32 session sites. The qualitative data were thematically analyzed manually using Excel, while the quantitative data was analyzed using STATA 17. Results: A total of 1140 telephonic surveys, 96 KIIs, and 16 FGDs were conducted. The study revealed that program managers mentioned maternal emotional reactions as a significant concern and backed AIV introduction at the 9–12 months touchpoint. Vaccinators and community mobilizers favored the 16–24 months window with combined presentations and mentioned single-dose vials as the preferred approach for vaccine delivery. Caregivers acknowledged the benefits of vaccination but expressed discomfort and fear regarding multiple injections to the child in a single visit. Caregivers expressed a preference for a combination vaccine. No preference was reported among caregivers for the introduction of AIV to the 9–12 or 16–24 months touchpoints. Conclusion: Stakeholders’ perspectives on introducing an additional injectable vaccine in a single visit under the UIP are diverse. These will be helpful in developing an effective strategy for the future introduction of AIV under UIP.
Open AccessStakeholders Perspectives on the Introduction of an Additional Injectable Vaccine Under the Universal Immunization Programme in India
Introduction: In 2023, India’s National Technical Advisory Group on Immunization (NTAGI) recommended the inclusion of typhoid conjugate vaccine (TCV) in the Universal Immunization Programme (UIP). However, introducing TCV, an additional injectable vaccine (AIV), will potentially increase the number of injections administered in a single visit to a maximum of five (if given at the 9 to 12 months touchpoint) or four (if given in the second year of life). In this context, the present study aimed to explore the perspectives of program managers, service providers, and caregivers regarding introduction of an AIV in a single visit under the UIP. Methods: A mixed-method study was undertaken wherein quantitative data was collected by telephonic surveys, and qualitative data by key informant interviews (KIIs) and focus group discussions (FGDs). Purposive sampling encompassed eight states, eight districts, eight planning units, and 32 session sites. The qualitative data were thematically analyzed manually using Excel, while the quantitative data was analyzed using STATA 17. Results: A total of 1140 telephonic surveys, 96 KIIs, and 16 FGDs were conducted. The study revealed that program managers mentioned maternal emotional reactions as a significant concern and backed AIV introduction at the 9–12 months touchpoint. Vaccinators and community mobilizers favored the 16–24 months window with combined presentations and mentioned single-dose vials as the preferred approach for vaccine delivery. Caregivers acknowledged the benefits of vaccination but expressed discomfort and fear regarding multiple injections to the child in a single visit. Caregivers expressed a preference for a combination vaccine. No preference was reported among caregivers for the introduction of AIV to the 9–12 or 16–24 months touchpoints. Conclusion: Stakeholders’ perspectives on introducing an additional injectable vaccine in a single visit under the UIP are diverse. These will be helpful in developing an effective strategy for the future introduction of AIV under UIP.
- Open Access
- 20 February 2025
- Published by MDPI AG in Preprints.org
Chronicling the Journey of Pneumococcal Conjugate Vaccine Introduction in India
Background: Pneumonia is one of the leading causes of death in under-5 children in India. The phased rollout, which began in high-burden states and was completed nationwide by 2021, was a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite challenges posed by the COVID-19 pandemic, which affected logistics and required creative solutions, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, dedication and coordinated efforts of various stakeholders involved that led to accomplishment of successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to the burden of pneumonia, pneumococcal pneumonia mortality in children under five, the efficacy and effectiveness of Pneumococcal Conjugate Vaccines (PCVs), and the documentation of PCV introduction and scale-up in India was carried out. Results: The documentation of PCV journey has been broken down in four sections: pre-introduction, PCV Phase I introduction, Pan India rapid expansion, and post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased reflecting successful immunization efforts. The WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) also show a positive trend in vaccination coverage, which aligns with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). Conclusion: The phased rollout, starting with high-burden states and completing nationwide expansion by 2021, was an ambitious effort by the Ministry of Health and Family Welfare (MoHFW), particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. This is a noteworthy achievement considering the unprecedented scale of the COVID-19 vaccination drive that was simultaneously ongoing.
- 20 February 2025
- Published by MDPI AG in Preprints.org
Open AccessChronicling the Journey of Pneumococcal Conjugate Vaccine Introduction in India
Background: Pneumonia is one of the leading causes of death in under-5 children in India. The phased rollout, which began in high-burden states and was completed nationwide by 2021, was a major initiative by the Ministry of Health and Family Welfare (MoHFW). Despite challenges posed by the COVID-19 pandemic, which affected logistics and required creative solutions, the campaign succeeded in maintaining progress and achieving nationwide coverage. This narrative review highlights the significant decisions, dedication and coordinated efforts of various stakeholders involved that led to accomplishment of successful PCV rollout. Methodology: A comprehensive desk review of both published and unpublished literature relevant to the burden of pneumonia, pneumococcal pneumonia mortality in children under five, the efficacy and effectiveness of Pneumococcal Conjugate Vaccines (PCVs), and the documentation of PCV introduction and scale-up in India was carried out. Results: The documentation of PCV journey has been broken down in four sections: pre-introduction, PCV Phase I introduction, Pan India rapid expansion, and post-introduction. Since the nationwide rollout in 2021, PCV coverage in India has steadily increased reflecting successful immunization efforts. The WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) also show a positive trend in vaccination coverage, which aligns with the goals of the WHO and UNICEF’s Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). Conclusion: The phased rollout, starting with high-burden states and completing nationwide expansion by 2021, was an ambitious effort by the Ministry of Health and Family Welfare (MoHFW), particularly challenging given the overlap with the COVID-19 pandemic. Despite these hurdles, the MoHFW, with strong collaboration from development partners and stakeholders, successfully navigated the complex rollout. This is a noteworthy achievement considering the unprecedented scale of the COVID-19 vaccination drive that was simultaneously ongoing.
- Open Access
- 16 January 2025
- Published by MDPI AG in Preprints.org
Exploring the Predictors for the Uptake of an Additional Maternal Vaccine Under the Immunization Programme in India
Introduction: Maternal immunization (MI) has evolved over the past decade, protecting both mother and offspring from infectious diseases. In India, only one vaccine, tetanus toxoid (TT)/ tetanus and diphtheria (Td), is available under the Universal Immunization Programme (UIP) for pregnant women. However, the basket of MI can be expanded by introducing the additional maternal vaccines in the immunization schedule. The study aims to explore the potential predictors for the uptake of additional maternal vaccines under UIP. Methodology: For the study, relevant data was extracted from the National Family Health Survey (NFHS-5) conducted during 2019-21. A cross-sectional sample of women aged 15-49 years who had given birth in the past 5 years was analyzed. Bivariate statistics and logistic regression analysis were employed to assess the predictors for pregnant women's interaction with healthcare workers (HCWs) during 3rd trimester of pregnancy using Stata 17 software. This measure was used as a proxy to gauge readiness for new vaccine introductions, like RSV, administered during the third trimester. Results: Information from 174,483 women was included in the study. Of them, 59.3% went for four or more antenatal care (ANC) visits, and a significant proportion (83.8%) received tetanus injections. The number of antenatal visits and tetanus injections during pregnancy emerged as strong predictors, with higher ANC visit frequencies with increased odds of meeting with healthcare workers (HCWs) during the third trimester of pregnancy. Further, younger age (20-24 years), middle wealth index group, and residence in rural areas were identified as positive predictors while higher levels of education emerged as a negative predictor. Conclusion: The study highlights the importance of ANC visits and tetanus vaccine uptake in engaging pregnant women with HCWs during the third trimester. These factors indicate readiness for potential interventions, like the RSV vaccine, and suggest leveraging ANC visits for introducing new maternal immunization vaccines.
- 16 January 2025
- Published by MDPI AG in Preprints.org
Open AccessExploring the Predictors for the Uptake of an Additional Maternal Vaccine Under the Immunization Programme in India
Introduction: Maternal immunization (MI) has evolved over the past decade, protecting both mother and offspring from infectious diseases. In India, only one vaccine, tetanus toxoid (TT)/ tetanus and diphtheria (Td), is available under the Universal Immunization Programme (UIP) for pregnant women. However, the basket of MI can be expanded by introducing the additional maternal vaccines in the immunization schedule. The study aims to explore the potential predictors for the uptake of additional maternal vaccines under UIP. Methodology: For the study, relevant data was extracted from the National Family Health Survey (NFHS-5) conducted during 2019-21. A cross-sectional sample of women aged 15-49 years who had given birth in the past 5 years was analyzed. Bivariate statistics and logistic regression analysis were employed to assess the predictors for pregnant women's interaction with healthcare workers (HCWs) during 3rd trimester of pregnancy using Stata 17 software. This measure was used as a proxy to gauge readiness for new vaccine introductions, like RSV, administered during the third trimester. Results: Information from 174,483 women was included in the study. Of them, 59.3% went for four or more antenatal care (ANC) visits, and a significant proportion (83.8%) received tetanus injections. The number of antenatal visits and tetanus injections during pregnancy emerged as strong predictors, with higher ANC visit frequencies with increased odds of meeting with healthcare workers (HCWs) during the third trimester of pregnancy. Further, younger age (20-24 years), middle wealth index group, and residence in rural areas were identified as positive predictors while higher levels of education emerged as a negative predictor. Conclusion: The study highlights the importance of ANC visits and tetanus vaccine uptake in engaging pregnant women with HCWs during the third trimester. These factors indicate readiness for potential interventions, like the RSV vaccine, and suggest leveraging ANC visits for introducing new maternal immunization vaccines.
- Open Access
- 1 November 2024
- Published by Elsevier in Vaccine: X
- Vol. 21, 100578
Lot quality assurance sampling for coverage evaluation of a new vaccine: A pilot study
- 1 November 2024
- Published by Elsevier in Vaccine: X
- Vol. 21, 100578
Open AccessLot quality assurance sampling for coverage evaluation of a new vaccine: A pilot study